Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LILIANA BUSTAMANTE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1881987303
CMS profile
1311903
Location
CAPE CORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$16,929.74

147 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LILIANA BUSTAMANTE

NPI 1881987303 · CMS profile ID 1311903

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

CAPE CORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881987303?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LILIANA BUSTAMANTE, NPI 1881987303, CMS profile ID 1311903. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881987303?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LILIANA BUSTAMANTE, NPI 1881987303, CMS profile ID 1311903. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881987303?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LILIANA BUSTAMANTE, NPI 1881987303, CMS profile ID 1311903, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1881987303?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

147 matching records · $16,929.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 147 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 147.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $13.6309/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991458727 CMS
Bayer Healthcare Pharmaceuticals Inc. $1,083.0009/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000531505 CMS
Bayer Healthcare Pharmaceuticals Inc. $1,083.0009/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061689505 CMS
E.R. Squibb & Sons, L.L.C. $12.0709/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015167247 CMS
Mirati Therapeutics, Inc. $17.2409/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057987435 CMS
ARRAY BIOPHARMA INC $16.3709/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050138097 CMS
Seagen Inc. $12.1009/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995790857 CMS
Amgen Inc. $6.8509/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020001121 CMS
GlaxoSmithKline, LLC. $15.7608/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001790763 CMS
Janssen Biotech, Inc. $19.6008/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988336809 CMS
Janssen Biotech, Inc. $5.8708/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988336835 CMS
Astellas Pharma US Inc $16.8608/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034442515 CMS
Incyte Corporation $27.9708/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044555297 CMS
Janssen Biotech, Inc. $12.0908/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988336797 CMS
Seagen Inc. $2.9808/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995790791 CMS
Merck Sharp & Dohme LLC $11.2308/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048255645 CMS
E.R. Squibb & Sons, L.L.C. $12.1308/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015167205 CMS
Incyte Corporation $19.7708/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044555211 CMS
G1 Therapeutics, Inc. $19.8208/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059919273 CMS
Merck Sharp & Dohme LLC $28.9008/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048255849 CMS
Merck Sharp & Dohme LLC $22.7208/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048255857 CMS
PFIZER INC. $20.3108/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049969553 CMS
Seagen Inc. $23.0008/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995790878 CMS
Amgen Inc. $10.0508/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020624377 CMS
Amgen Inc. $3.0208/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020001119 CMS
Celgene Corporation $19.0108/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015167183 CMS
PFIZER INC. $19.8708/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050095405 CMS
Merck Sharp & Dohme LLC $24.9707/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048846875 CMS
Amgen Inc. $2.8107/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020001117 CMS
ImmunoGen, Inc. $13.5507/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017250067 CMS
Novartis Pharmaceuticals Corporation $24.0707/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991458723 CMS
Astellas Pharma US Inc $14.1207/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034292899 CMS
Novartis Pharmaceuticals Corporation $12.4507/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991458719 CMS
Amgen Inc. $3,000.0007/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020001127 CMS
Novartis Pharmaceuticals Corporation $11.7607/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991458715 CMS
MorphoSys, US Inc. $15.6007/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060329333 CMS
PFIZER INC. $18.8906/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049940935 CMS
Gilead Sciences, Inc. $23.9606/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025674515 CMS
Amgen Inc. $3.1906/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020001115 CMS
PFIZER INC. $19.5606/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049949787 CMS
Merck Sharp & Dohme LLC $22.5606/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048255847 CMS
Amgen Inc. $124.6406/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020001129 CMS
Astellas Pharma US Inc $14.7106/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034202769 CMS
Janssen Biotech, Inc. $21.3806/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988336901 CMS
Incyte Corporation $23.7006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044555123 CMS
Janssen Biotech, Inc. $15.8706/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988336889 CMS
Janssen Biotech, Inc. $15.8206/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988336943 CMS
Gilead Sciences, Inc. $23.4706/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025692605 CMS
ARRAY BIOPHARMA INC $16.1306/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049276047 CMS
Celgene Corporation $23.1706/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015167161 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,494.77 77
PY2020 $1,128.21 62
PY2021 $4,072.69 67
PY2022 $1,716.79 99
PY2023 $16,929.74 147
PY2024 $7,032.76 164
PY2025 $2,618.98 117

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $273,683.67 6
PY2024 Principal investigator $111,393.11 4
PY2023 Recipient $42,184.35 2
PY2023 Principal investigator $28,326.81 2
PY2022 Recipient $49,192.00 1
PY2022 Principal investigator $37,142.00 1
PY2021 Principal investigator $16,700.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

6 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $400.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185542592
Principal investigator 1 Merck Sharp & Dohme LLC $35,345.48 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists - South
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT Sacituzumab Tirumotecan, MK-2870 Followed by Carboplatin,Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Earl No dispute reported 06/30/2026 1232924568
Principal investigator 1 AstraZeneca Pharmaceuticals LP $58,596.59 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185542590
Principal investigator 1 Eli Lilly and Company $83.75 02/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187889030
Principal investigator 1 AstraZeneca Pharmaceuticals LP $132,179.63 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185542594
Principal investigator 1 Eli Lilly and Company $47,078.22 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187887470